Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Larimar Therapeutics ( (LRMR) ) has issued an update.
On September 29, 2025, Larimar Therapeutics announced positive results from their ongoing long-term open-label study of nomlabofusp for Friedreich’s ataxia. The study showed improvements in clinical outcomes and increased skin frataxin levels, suggesting potential clinical benefits. Despite some cases of anaphylaxis, the treatment was generally well-tolerated, leading to a modified starting dose regimen approved by the FDA. The company plans to seek accelerated approval in Q2 2026, highlighting the potential of nomlabofusp as a disease-modifying therapy.
The most recent analyst rating on (LRMR) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.
Spark’s Take on LRMR Stock
According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.
Larimar Therapeutics’ stock score reflects its early-stage biotech status with high R&D costs, no consistent revenue, and reliance on equity financing. Despite positive short-term technical indicators suggesting upward momentum, the lack of profitability and a negative P/E ratio weigh heavily on the stock. Valuation concerns and the absence of earnings call insights further impact the score.
To see Spark’s full report on LRMR stock, click here.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company is particularly involved in creating therapies for Friedreich’s ataxia, a rare, progressive, and systemic disease characterized by neurologic deterioration.
Average Trading Volume: 1,549,769
Technical Sentiment Signal: Hold
Current Market Cap: $436.1M
See more insights into LRMR stock on TipRanks’ Stock Analysis page.